Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Swedish (OMX) Healthcare Sector Analysis

UpdatedJan 08, 2026
DataAggregated Company Financials
Companies151
  • 7D1.2%
  • 3M-2.9%
  • 1Y-3.9%
  • YTD2.8%

Over the last 7 days, the Healthcare industry has dropped 1.6%, driven by a pullback from Sectra of 3.7%. Overall the industry is down 3.9% in 12 months. As for the next few years, earnings are expected to grow by 26% per annum.

Sector Valuation and Performance

Has the Swedish Healthcare Sector valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Fri, 09 Jan 2026SEK 595.8bSEK 230.2bSEK 3.7b42.5x162.3x2.6x
Sun, 07 Dec 2025SEK 595.3bSEK 230.8bSEK 3.6b42.6x167.7x2.6x
Tue, 04 Nov 2025SEK 604.3bSEK 228.2bSEK 3.4b45.5x180.1x2.6x
Thu, 02 Oct 2025SEK 607.1bSEK 227.1bSEK 6.6b43.1x91.9x2.7x
Sat, 30 Aug 2025SEK 624.6bSEK 227.0bSEK 6.5b46.8x96.6x2.8x
Mon, 28 Jul 2025SEK 639.6bSEK 226.9bSEK 6.5b54.5x97.8x2.8x
Wed, 25 Jun 2025SEK 605.1bSEK 226.7bSEK 5.9b44.2x103.3x2.7x
Fri, 23 May 2025SEK 593.2bSEK 226.1bSEK 6.7b37.6x88.9x2.6x
Sun, 20 Apr 2025SEK 547.9bSEK 221.4bSEK 5.2b32.3x106.1x2.5x
Tue, 18 Mar 2025SEK 557.9bSEK 206.3bSEK 4.9b37.1x113.9x2.7x
Thu, 13 Feb 2025SEK 594.7bSEK 204.7bSEK 1.9b42.1x306.5x2.9x
Sat, 11 Jan 2025SEK 581.1bSEK 202.7b-SEK 2,498,875,309.5841.1x-232.5x2.9x
Mon, 09 Dec 2024SEK 574.5bSEK 202.6b-SEK 2,458,596,674.2638.4x-233.7x2.8x
Wed, 06 Nov 2024SEK 525.5bSEK 200.1b-SEK 2,883,076,729.2037.5x-182.3x2.6x
Fri, 04 Oct 2024SEK 607.1bSEK 200.1b-SEK 2,782,783,187.3139x-218.2x3x
Sun, 01 Sep 2024SEK 616.6bSEK 200.0b-SEK 2,803,385,491.0341.3x-219.9x3.1x
Tue, 30 Jul 2024SEK 586.9bSEK 200.0b-SEK 2,850,253,755.3441.3x-205.9x2.9x
Thu, 27 Jun 2024SEK 558.9bSEK 195.6b-SEK 3,183,088,481.9836.4x-175.6x2.9x
Sat, 25 May 2024SEK 553.7bSEK 196.1b-SEK 2,796,169,497.7836.5x-198x2.8x
Mon, 22 Apr 2024SEK 509.5bSEK 193.1b-SEK 3,154,359,283.3344.5x-161.5x2.6x
Wed, 20 Mar 2024SEK 517.0bSEK 192.4b-SEK 3,668,848,510.3543.6x-140.9x2.7x
Fri, 16 Feb 2024SEK 515.4bSEK 191.2b-SEK 4,131,757,269.2449.6x-124.7x2.7x
Sun, 14 Jan 2024SEK 558.9bSEK 191.5b-SEK 965,181,563.0048.1x-579.1x2.9x
Tue, 12 Dec 2023SEK 505.1bSEK 190.5b-SEK 1,068,465,929.0050.6x-472.8x2.7x
Thu, 09 Nov 2023SEK 462.5bSEK 190.1b-SEK 1,189,319,911.0048.2x-388.9x2.4x
Sat, 07 Oct 2023SEK 447.6bSEK 185.1b-SEK 2,032,365,793.0034.3x-220.2x2.4x
Mon, 04 Sep 2023SEK 467.5bSEK 185.6b-SEK 1,979,325,492.0038.7x-236.2x2.5x
Wed, 02 Aug 2023SEK 479.7bSEK 183.9b-SEK 984,207,190.0039.9x-487.4x2.6x
Fri, 30 Jun 2023SEK 475.4bSEK 179.3b-SEK 796,616,736.0044.3x-596.7x2.7x
Sun, 28 May 2023SEK 515.6bSEK 178.7b-SEK 548,140,751.0044.1x-940.7x2.9x
Tue, 25 Apr 2023SEK 512.0bSEK 173.1b-SEK 1,483,819,369.0034.2x-345x3x
Thu, 23 Mar 2023SEK 479.2bSEK 172.3b-SEK 1,415,465,557.0036.2x-338.6x2.8x
Sat, 18 Feb 2023SEK 504.1bSEK 169.4b-SEK 107,218,617.0034.9x-4701.5x3x
Mon, 16 Jan 2023SEK 505.2bSEK 165.8bSEK 697.8m33.8x723.9x3x
Price to Earnings Ratio

723.9x


Total Market Cap: SEK 505.2bTotal Earnings: SEK 697.8mTotal Revenue: SEK 165.8bTotal Market Cap vs Earnings and Revenue0%0%0%
Swedish Healthcare Sector Price to Earnings3Y Average -136.2x202420252026
Current Industry PE
  • Investors are optimistic on the Swedish Healthcare industry, and appear confident in long term growth rates.
  • The industry is trading at a PE ratio of 162x which is higher than its 3-year average PE of -136x.
  • The industry is trading close to its 3-year average PS ratio of 2.7x.
Past Earnings Growth
  • The earnings for companies in the Healthcare industry have grown 74% per year over the last three years.
  • Revenues for these companies have grown 12% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Swedish Healthcare sector?

SE Market2.26%
Healthcare1.24%
Medical Equipment3.03%
Pharma2.56%
Biotech1.69%
Healthcare Services0.50%
Life Sciences-1.51%
Healthtech-3.25%
Industry PE
  • Investors are most optimistic about the Healthtech industry even though it's trading below its 3-year average PE ratio of 122x.
    • Analysts are expecting annual earnings growth of 17.6%, which is lower than the prior year's growth of 46.7% per year.
Forecasted Growth
  • Analysts are most optimistic on the Pharma industry, expecting annual earnings growth of 35% over the next 5 years.
  • However this is lower than its past earnings growth rate of 97% per year.
  • In contrast, the Healthtech industry is expected to see its earnings grow by 18% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
SOBI Swedish Orphan BiovitrumSEK 346.204.0%
+SEK 4.6b		8.2%PE9178.5x
BIOA B BioArcticSEK 332.807.1%
+SEK 2.0b		62.7%PE29.5x
GETI B GetingeSEK 225.002.8%
+SEK 1.7b		21.2%PE29.8x
CAMX CamurusSEK 638.503.7%
+SEK 1.3b		7.4%PE48.7x
VIMIAN Vimian GroupSEK 32.065.7%
+SEK 910.3m		-13.4%PE50.1x

Latest News

ASKER
SEK 86.50
Asker Healthcare Group
7D
2.5%
1Y
n/a
VIMIAN
SEK 32.06
Vimian Group
7D
5.7%
1Y
-13.4%

Returns On Capital Are Showing Encouraging Signs At Vimian Group (STO:VIMIAN)

Jan 08
Returns On Capital Are Showing Encouraging Signs At Vimian Group (STO:VIMIAN)
SOBI
SEK 346.20
Swedish Orphan Biovitrum
7D
4.0%
1Y
8.2%
ATT
SEK 85.00
Attendo
7D
3.8%
1Y
63.8%
ALIF B
SEK 155.10
AddLife
7D
-2.5%
1Y
16.1%

ALIF B: Stable Margins And Refined Discount Rate Will Support Future Upside Potential

Analysts have kept their fair value estimate for AddLife steady at SEK 208.50, with small tweaks to inputs like the discount rate and assumed future P/E reflecting fine tuning of their valuation approach, rather than a fundamental shift in their view of the company. Valuation Changes Fair Value Estimate unchanged at SEK 208.50 per share, indicating no revision to the overall target level.
HNSA
SEK 32.76
Hansa Biopharma
7D
-4.7%
1Y
-6.5%

HNSA: Buy Initiation And FDA Filing Will Shape Upside Potential

Analysts have adjusted their price view on Hansa Biopharma from SEK 143 to SEK 111, citing updated assumptions on discount rates, revenue growth, profit margins and future P/E, along with fresh coverage that includes a new SEK 100 target from Street research. Analyst Commentary Bullish analysts see the recent SEK 100 price target as a constructive marker for where Hansa Biopharma could trade if the company executes in line with their assumptions on revenue, margins and future P/E.
SECT B
SEK 236.20
Sectra
7D
-5.9%
1Y
-10.3%

SECT B: Cloud Imaging Contracts Will Support Stable Earnings Multiples And Balanced Outlook

Analysts have maintained their Sectra fair value estimate at SEK245.00, citing essentially unchanged assumptions for the discount rate, revenue growth, profit margin and future P/E, which together support a stable price target view. What's in the News Sectra will provide four NHS trusts in Lancashire and South Cumbria with a single Sectra One Cloud enterprise imaging solution, covering 15 hospitals and supporting care for around 1.8 million people through a unified radiology and breast imaging platform (Client Announcements).
OSSD
SEK 10.30
OssDsign
7D
-9.2%
1Y
-9.2%

OSSD: New US Focused Leadership Will Shape Bullish Future Outlook

Analysts have adjusted their price target on OssDsign to $13.50, reflecting updated assumptions around revenue growth, profit margin and a much higher implied future P/E multiple, while keeping their fair value estimate unchanged at $13.50. What's in the News OssDsign AB appointed Mark Waugh as CEO, effective January 1, 2026, following five years of leadership under outgoing CEO Morten Henneveld (Key Developments).
EKTA B
SEK 58.70
Elekta
7D
3.4%
1Y
-3.7%

EKTA B: Earnings Headwinds From FX And Tariffs Will Persist

Analysts have maintained their price target for Elekta at €39.00, making only modest adjustments to assumptions on discount rate, revenue growth, profit margin and future P/E. These changes consolidate their existing view rather than signaling a major shift in outlook.
CAMX
SEK 638.50
Camurus
7D
3.7%
1Y
7.4%

CAMX: Revised Outlook Will Balance Guidance Cut With Pipeline And Partnership Progress

Analysts have trimmed their Camurus fair value estimate from SEK 690.00 to SEK 660.00, citing updated assumptions for the discount rate, revenue growth, profit margin and future P/E. What's in the News Camurus revised its 2025 earnings guidance, now expecting total revenue of SEK 2.3b to SEK 2.6b, compared with the previous range of SEK 2.7b to SEK 3.0b, while keeping profit before tax guidance at SEK 0.9b to SEK 1.2b (Key Developments).
GETI B
SEK 225.00
Getinge
7D
2.8%
1Y
21.2%

Some Shareholders Feeling Restless Over Getinge AB (publ)'s (STO:GETI B) P/E Ratio

Jan 02
Some Shareholders Feeling Restless Over Getinge AB (publ)'s (STO:GETI B) P/E Ratio
EGTX
SEK 4.86
Egetis Therapeutics
7D
-9.0%
1Y
-28.5%
MCOV B
SEK 217.50
Medicover
7D
-1.4%
1Y
13.3%

MCOV B: MRD Study Progress Will Support Steady Long Term Outlook

Analysts have raised their price target on Medicover to SEK 230.73 per share, reflecting modestly stronger expectations for long term revenue growth and profit margins despite an essentially unchanged valuation framework. What's in the News Medicover reported additional data from the ongoing DART phase II clinical study at Oslo University Hospital, using Medicover Genetics' hybrid capture based, tumour agnostic MRD assay in unresectable stage III NSCLC patients (Key Developments).
BIOA B
SEK 332.80
BioArctic
7D
7.1%
1Y
62.7%

BIOA B Future Long Term Margin Upside Will Not Offset Demand Risks

Analysts have modestly raised their price target on BioArctic to SEK 230 (from SEK 230 previously), reflecting slightly lower perceived risk and a substantially improved long term profit margin outlook, despite marginally weaker revenue growth assumptions and a lower projected future P/E multiple. What's in the News Leqembi, developed by BioArctic and Eisai, has been included in China’s new Commercial Insurance Innovative Drug List.
VITR
SEK 135.00
Vitrolife
7D
-1.5%
1Y
-35.3%

VITR: Restructuring And Goodwill Impairment Will Support Future Upside Potential

Analysts have slightly reduced their price target on Vitrolife, trimming fair value by SEK 4.75 to SEK 188.75, as modestly higher long term growth assumptions are offset by a small downgrade to profitability and a lower expected valuation multiple. What's in the News Vitrolife plans to record a SEK 5.4 billion goodwill impairment in the fourth quarter of 2025 related to the Igenomix acquisition (company announcement).
RAY B
SEK 215.50
RaySearch Laboratories
7D
-5.5%
1Y
-5.5%